Tianjin Ringpu Bio-Technology Co.,Ltd.

Shenzhen Stock Exchange 300119.SZ

Tianjin Ringpu Bio-Technology Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 62.84 M

Tianjin Ringpu Bio-Technology Co.,Ltd. Total Non-Current Liabilities is USD 62.84 M for the year ending December 31, 2023, a 46.80% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Tianjin Ringpu Bio-Technology Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 42.81 M, a 11.77% change year over year.
  • Tianjin Ringpu Bio-Technology Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 38.30 M, a -12.28% change year over year.
  • Tianjin Ringpu Bio-Technology Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 43.66 M, a 89.75% change year over year.
  • Tianjin Ringpu Bio-Technology Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 23.01 M, a 101.40% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300119.SZ

Tianjin Ringpu Bio-Technology Co.,Ltd.

CEO Mr. Lei Xu
IPO Date Sept. 17, 2010
Location China
Headquarters No. 1, Dongjiu Road
Employees 2,496
Sector Healthcare
Industries
Description

Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sales of veterinary biological products, veterinary drug preparations, functional additives, and veterinary raw materials in China. The company provides vaccines and drugs for poultry, swine, and other animals; pet products comprising pet rabies inactivated vaccine, recombinant canine-a interferon, inhalation anesthetics isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate for injection for prevention and treatment of pet bacterial diseases, heart disease drugs for dogs and cats, napril chewable tablets and other products; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, florfenicol soluble powder, kanamycin injection, etc. It also offers antifungal products, such as natural plant extracts, immune polysaccharides, clostridium butyricum, lactobacillus plantarum, antibacterial peptides, enzyme preparations, acidulants, etc; disinfection and cleaning products, consisting of potassium hydrogen persulfate composite powder, benzyl trimethyl ammonium chloride solution, deca methyl ammonium bromide solution, sodium dichloroisocyanurate, iodine glycerin solution, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, gamimycin, etc. The company was founded in 1998 and is based in Tianjin, China.

StockViz Staff

February 2, 2025

Any question? Send us an email